RACHEL WERNER: Open Payments
NPI 1831642073 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,000 in 127 payments from 19 companies in 2025. Trend: 2023 $727 · 2024 $2,309 · 2025 $3,000
Food & beverage: $2,825Education: $175
| Company | Payments | Amount |
|---|---|---|
| REVANCE THERAPEUTICS, INC. | 5 | $570 |
| Novartis Pharmaceuticals Corporation | 17 | $307 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 9 | $274 |
| ABBVIE INC. | 14 | $220 |
| GENZYME CORPORATION | 6 | $185 |
| Janssen Biotech, Inc. | 5 | $155 |
| Lilly USA, LLC | 7 | $155 |
| Arcutis Biotherapeutics, Inc. | 8 | $145 |
| Regeneron Healthcare Solutions, Inc. | 3 | $144 |
| MAYNE PHARMA COMMERCIAL LLC | 16 | $142 |
Products named: DAXXIFY, DUPIXENT, COSENTYX, ILUMYA, TREMFYA, Zoryve, OPZELURA, TALTZ.
Industry payments across TX — which companies pay providers there.
